HRP20180712T1 - Postupci liječenja hematoloških oblika raka inhibitorima pnp, poput forodesina, u kombinaciji sa sredstvima protiv cd20 - Google Patents

Postupci liječenja hematoloških oblika raka inhibitorima pnp, poput forodesina, u kombinaciji sa sredstvima protiv cd20

Info

Publication number
HRP20180712T1
HRP20180712T1 HRP20180712TT HRP20180712T HRP20180712T1 HR P20180712 T1 HRP20180712 T1 HR P20180712T1 HR P20180712T T HRP20180712T T HR P20180712TT HR P20180712 T HRP20180712 T HR P20180712T HR P20180712 T1 HRP20180712 T1 HR P20180712T1
Authority
HR
Croatia
Prior art keywords
forodesine
agents
methods
combination
hematologic cancers
Prior art date
Application number
HRP20180712TT
Other languages
English (en)
Inventor
Shanta Bantia
Philip Breitfeld
Yarlagadda Sudhakara Babu
Original Assignee
Biocryst Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals, Inc. filed Critical Biocryst Pharmaceuticals, Inc.
Publication of HRP20180712T1 publication Critical patent/HRP20180712T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20180712TT 2007-12-10 2018-05-07 Postupci liječenja hematoloških oblika raka inhibitorima pnp, poput forodesina, u kombinaciji sa sredstvima protiv cd20 HRP20180712T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1276207P 2007-12-10 2007-12-10
EP12177257.8A EP2564846B1 (en) 2007-12-10 2008-12-10 Methods of treating hematologic cancers using PNP inhibitors such as forodesine in combination with Anti-CD20 agents

Publications (1)

Publication Number Publication Date
HRP20180712T1 true HRP20180712T1 (hr) 2018-06-15

Family

ID=40431122

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180712TT HRP20180712T1 (hr) 2007-12-10 2018-05-07 Postupci liječenja hematoloških oblika raka inhibitorima pnp, poput forodesina, u kombinaciji sa sredstvima protiv cd20

Country Status (26)

Country Link
US (5) US20110038858A1 (hr)
EP (3) EP2564846B1 (hr)
JP (2) JP5543362B2 (hr)
KR (1) KR101545367B1 (hr)
CN (2) CN101969947B (hr)
AU (1) AU2008335167B2 (hr)
CA (2) CA2881035C (hr)
CY (1) CY1120203T1 (hr)
DK (1) DK2564846T3 (hr)
EA (2) EA018415B1 (hr)
ES (1) ES2670714T3 (hr)
GE (2) GEP20135855B (hr)
HR (1) HRP20180712T1 (hr)
HU (1) HUE037342T2 (hr)
IL (1) IL206264A (hr)
LT (1) LT2564846T (hr)
MY (2) MY163023A (hr)
NO (1) NO2564846T3 (hr)
NZ (3) NZ601072A (hr)
PH (1) PH12014501454B1 (hr)
PL (1) PL2564846T3 (hr)
PT (1) PT2564846T (hr)
SG (1) SG188870A1 (hr)
SI (1) SI2564846T1 (hr)
UA (2) UA104579C2 (hr)
WO (1) WO2009076455A2 (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9452217B2 (en) 2013-06-22 2016-09-27 Nitor Therapeutics Methods for potentiating immune response for the treatment of infectious diseases and cancer
ES2909662T3 (es) * 2014-08-07 2022-05-09 Laevoroc Immunology Ag Composiciones que comprenden un inhibidor de PNP para uso en el tratamiento de la recaída de malignidad después de un trasplante de células madre hematopoyéticas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199697A (en) 1878-01-29 Improvement in butter-sharers
JP2760364B2 (ja) 1989-02-27 1998-05-28 バイオクライシス・ファーマシューティカルズ、インコーポレイテッド ９―置換―８―非置換―９―デアザグアニン類
US4985434A (en) 1989-10-31 1991-01-15 Biocryst, Inc. 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same
US5008265A (en) 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5008270A (en) 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US4985433A (en) 1989-10-31 1991-01-15 Biocryst, Inc. 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
BR9509236A (pt) * 1994-10-05 1997-10-21 Chiroscience Ltd Compostos purina e guanina como inibidores de pnp
KR20010103655A (ko) * 1998-11-09 2001-11-23 케네쓰 제이. 울코트 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법
US6387923B2 (en) * 2000-03-22 2002-05-14 Biocryst Pharmacueticals, Inc. Imminoribitol PNP inhibitors, preparation thereof and use thereof
DE10306724A1 (de) * 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
MXPA04011311A (es) * 2002-05-17 2005-02-14 Celgene Corp Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y el manejo de canceres y otras enfermedades.
WO2007002931A2 (en) * 2005-06-29 2007-01-04 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy

Also Published As

Publication number Publication date
PL2564846T3 (pl) 2018-08-31
SI2564846T1 (en) 2018-06-29
KR20100101139A (ko) 2010-09-16
JP5543362B2 (ja) 2014-07-09
PH12014501454A1 (en) 2016-01-18
CA2708606A1 (en) 2009-06-18
JP2011506345A (ja) 2011-03-03
US20240100055A1 (en) 2024-03-28
EP2237778A2 (en) 2010-10-13
PH12014501454B1 (en) 2016-01-18
CN103736091B (zh) 2016-09-28
CA2708606C (en) 2015-04-28
EP2564846B1 (en) 2018-02-28
KR101545367B1 (ko) 2015-08-18
MY193789A (en) 2022-10-27
EA201370055A1 (ru) 2013-11-29
NO2564846T3 (hr) 2018-07-28
NZ586416A (en) 2012-07-27
CA2881035C (en) 2019-04-16
CY1120203T1 (el) 2018-12-12
CN103736091A (zh) 2014-04-23
IL206264A (en) 2017-04-30
CN101969947A (zh) 2011-02-09
DK2564846T3 (en) 2018-05-22
MY163023A (en) 2017-07-31
GEP20135855B (en) 2013-06-25
US20220040188A1 (en) 2022-02-10
LT2564846T (lt) 2018-05-10
EP2564846A1 (en) 2013-03-06
WO2009076455A2 (en) 2009-06-18
US20110038858A1 (en) 2011-02-17
AU2008335167A1 (en) 2009-06-18
GEP20156288B (en) 2015-05-25
EA201070669A1 (ru) 2010-12-30
JP2014094962A (ja) 2014-05-22
US20140178372A1 (en) 2014-06-26
AU2008335167B2 (en) 2014-02-13
UA109571C2 (uk) 2015-09-10
NZ601072A (en) 2014-01-31
WO2009076455A3 (en) 2009-08-27
US20190255058A1 (en) 2019-08-22
EA025340B1 (ru) 2016-12-30
UA104579C2 (uk) 2014-02-25
EA018415B1 (ru) 2013-07-30
IL206264A0 (en) 2010-12-30
ES2670714T3 (es) 2018-05-31
NZ617989A (en) 2015-05-29
CN101969947B (zh) 2014-10-22
SG188870A1 (en) 2013-04-30
EP2581083A1 (en) 2013-04-17
PT2564846T (pt) 2018-05-23
US11110092B2 (en) 2021-09-07
HUE037342T2 (hu) 2018-08-28
CA2881035A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
EP2429574A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMATOLOGICAL CANCERS, TARGETING THE SIRP INTERACTION -CD47
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
EP2109687A4 (en) MICRO-RNA-BASED METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOUS LEUKEMIA (AML)
IL227746A0 (en) Methods and compositions for the treatment of cancer
PL2427441T3 (pl) Aktywatory PKM2 do stosowania w leczeniu raka
IL201211A (en) K3 ip-alpha quinoxaline inhibitors for use in combination with chemotherapeutic agents for use in the treatment of cancer
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
HRP20130642T1 (en) Methods and compositions for treating cancers
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
ZA201103964B (en) 7-hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
IL199881A0 (en) Compositions and methods for treating hematopietic malignancies
EP2231365A4 (en) GRINDING BODY AND MANUFACTURING METHOD THEREFOR
HRP20180712T1 (hr) Postupci liječenja hematoloških oblika raka inhibitorima pnp, poput forodesina, u kombinaciji sa sredstvima protiv cd20
HK1151971A1 (en) Compounds for use in the treatment of cancer
IL209973A (en) Materials and methods for the suppression and / or treatment of the nerve and associated tumors
EP2195650A4 (en) METHOD FOR THE TREATMENT OF TUMORS AT IMMUNRIVILEGED PLACES
EP2200627A4 (en) METHOD AND COMPOSITIONS FOR TREATING MELANOMA
AU2015201757A1 (en) Compositions and methods for treating hematologic cancers targeting the SIRPalpha - CD47 interaction
HK1172547A1 (en) Activin-actrii antagonists for use in treating anemia -actrii
EP2068629A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
IL198070A (en) Sirna molecules for use in the treatment of damage are caused by ischemia